Press Releases Archives | Page 106 of 116

Irvine Scientific Introduces Chemically-Defined Natural Killer Cell Expansion Medium for Immunotherapy & Translational Research Applications

July 24, 2018 By Cade Hildreth, Founder & President Leave a Comment

The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells

July 2018, Santa Ana, Calif. — Irvine Scientific, an industry leader in the development and manufacture of cell culture media, announced the introduction of PRIME-XV^® NK Cell CDM— the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The advanced medium delivers natural killer (NK) cell expansion while preserving NK cell potency and functionality. [Read more…]

Two-Year-Old Emirati Boy Saves Older Brother with Stem Cells Stored with CryoSave Arabia

July 18, 2018 By Cade Hildreth, Founder & President 1 Comment

Cryo-Save Arabia - Sickle-Cell — Hamad Alyaarbi

Dubai, UAE, July 2018 – Hamad Alyaarbi an eight-year-old Emirati boy who suffers from the debilitating condition Sickle Cell Anemia, has had his disease cured thanks to the use of stem cells from his younger brother, Abdullah, that were stored by CryoSave Arabia. At the beginning of 2017 Hamad’s parents had made the decision to use the cord blood stem cells from his younger brother, Abdullah, for a transplant to try and save his life. The transplant took place on 23rd June 2017, and almost a year later, Hamad is now completely cured and living a happy, healthy life, disease-free. [Read more…]

Steminent Announces FDA Approval of IND for Phase II Clinical Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia

July 18, 2018 By Cade Hildreth, Founder & President Leave a Comment

San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]

Nohla Therapeutics Secures $45 Million to Develop Cord Blood Treatment for Leukemia

May 17, 2018 By Cade Hildreth, Founder & President Leave a Comment

Nohla Therapeutics Announces Closing of $45 Million Series B Financing

Proceeds to Support the Development of Dilanubicel (NLA101) and Additional Platform Programs

Seattle, WA; May 15, 2018 – Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. [Read more…]

BioStem Technologies Inc. Announces Engagement of Dr. Felix Amon for Pharmaceutical Business Development

March 14, 2018 By Cade Hildreth, Founder & President Leave a Comment

Pompano Beach, FL, March 13, 2018 — BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
[Read more…]